It is reported that X-linked Dystonia-Parkinsonism (XDP), caused by a non-coding retrotransposon-associated repeat insertion in TAF1, involves a significant imbalance of tau isoforms and the accumulation of hyperphosphorylated, four-repeat tau in the brain.
Abstract
Tauopathies encompass diverse neurodegenerative diseases unified by aberrant patterns of tau deposition in brain. Although most appear sporadic, some are linked to genetic etiologies that offer unique mechanistic insights. Here we report that X-linked Dystonia-Parkinsonism (XDP), caused by a non-coding retrotransposon-associated repeat insertion in TAF1, involves a significant imbalance of tau isoforms and the accumulation of hyperphosphorylated, four-repeat tau in the brain. In striatal tissue, both misfolded tau accumulation, predominantly in astrocytes, and MAPT exon 10 inclusion correlated with repeat length within the causal insertion. Transcriptomic profiling across brain regions revealed dysregulation of known tau-related pathways. Levels of phosphorylated tau181, glial fibrillary acidic protein, and neurofilament light chain were elevated in patient plasma and discriminated XDP from controls. These findings implicate defective tau proteostasis as a key pathogenic mechanism and position XDP as a genetic model for uncovering cellular drivers that may disrupt tau in other more common neurodegenerative diseases.
A holistic perspective is provided by synthesizing recent developments in the molecular and genetic architecture of tauopathies, particularly newly discovered genetic risk loci and cellular proteostasis mechanisms to analytically evaluate the diagnostic value of fluid biomarkers and current data on next-generation clin...
E. Ünal, S. Çomoğlu· Journal of Parkinson's Disea...· 0 citations
Findings identify circTau6/cTau4R as a post-transcriptional mechanism that modulates tauopathy and partially recapitulated molecular signatures observed in human tauopathic brains.
Guangtong Jiang, Dan-Ni Wang, Lin Shao et al.· Molecular Psychiatry· 0 citations
A novel PIAS1-GSK3β signaling axis in tauopathy and a cell-permeable blocking peptide designed to disrupt the PIAS1-GSK3β interaction are uncovered and provide a promising targeted therapeutic strategy for Alzheimer's disease.
You-Lan Qiu, Suo Wu, Yi Zhong et al.· Molecular Psychiatry· 1 citation
A new Drosophila tauopathy model expressing eGFP-tagged human TauWT or the disease-associated TauP301L variant in the nervous system is established and 5-HT7R signaling is identified as a conserved and druggable modifier of Tau toxicity.
Mariana I. Tsap, Valeriya V. Navrotska, J. Labus et al.· bioRxiv· 0 citations
Findings support a model in which tau dysfunction results from the convergence of molecular aberrations and genetic susceptibility within a pathological network involving amyloid-β, neuroinflammation, and synaptic failure.
S. Sura, S. Jagadeesan, M. A. M. Moklas et al.· Molecular Biology Reports· 0 citations
A genome‐wide association study of tau‐related neurodegeneration identified two novel genetic variants in the loci AKAP9 and STXBP6 leading to higher than expected regional neurodegeneration given the tau level.
F. Nabizadeh, Hanieh Mohamadi· CNS Neuroscience & Therapeut...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.